Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Cerebellum ; 22(4): 578-586, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35655106

RESUMEN

Episodic ataxia type 1 (EA1) is a rare autosomal potassium channelopathy, due to mutations in KCNA1. Patients have childhood onset of intermittent attacks of ataxia, dizziness or imbalance. In order to quantify the natural history of EA1, its effect on quality of life and in preparation for future clinical trials, we set up an international multi-centre study of EA1. We recruited thirty-three participants with EA1: twenty-three completed 1-year follow-up and eighteen completed 2-year follow-up. There was very little accumulation of disability or impairment over the course of the 2 years of the study. The outcome measures of ataxia (SARA and functional rating of ataxia) and the activities of daily living scale were largely stable over time. Self-reported health-related quality of life (SF-36) scores were lower across all domains than controls, in keeping with a chronic condition. Physical subdomain scores appeared to deteriorate over time, which seems to be driven by the female participants in the study. This is an interesting finding and warrants further study. Attacks of EA1 reported by participants in real time via an interactive voice response system showed that symptoms were not stereotyped; however, attack duration and frequency was stable between individuals. This large prospective study is the first ever completed in subjects with EA1. We document the natural history of the disorder over 2 years. These data will enable the development of outcome measures for clinical trials of treatment.


Asunto(s)
Actividades Cotidianas , Calidad de Vida , Humanos , Femenino , Niño , Estudios Prospectivos , Canal de Potasio Kv.1.1/genética , Ataxia/diagnóstico
2.
J Inherit Metab Dis ; 45(4): 796-803, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35543492

RESUMEN

Primary mitochondrial disorders encompass a wide range of clinical presentations and a spectrum of severity. They currently lack effective disease-modifying therapies and have a high mortality and morbidity rate. It is therefore essential to know that competitively funded research designed by academics meets the core needs of people with mitochondrial disorders and their clinicians. Priority setting partnerships are an established collaborative methodology that brings patients, carers and families, charity representatives and clinicians together to try to establish the most pressing and unanswered research priorities for a particular disease. We developed a web-based questionnaire, requesting all patients affected by primary mitochondrial disease, their carers and clinicians to pose their research questions. This yielded 709 questions from 147 participants. These were grouped into overarching themes including basic biology, causation, health services, clinical management, social impacts, prognosis, prevention, symptoms, treatment and psychological impact. Following the removal of "answered questions", the process resulted in a list of 42 discrete, answerable questions. This was further refined by web-based ranking by the community to 24 questions. These were debated at a face-to-face workshop attended by a diverse range of patients, carers, charity representatives and clinicians to create a definitive "Top 10 of unanswered research questions for primary mitochondrial disorders". These Top 10 questions related to understanding biological processes, including triggers of disease onset, mechanisms underlying progression and reasons for differential symptoms between individuals with identical genetic mutations; new treatments; biomarker discovery; psychological support and optimal management of stroke-like episodes and fatigue.


Asunto(s)
Investigación Biomédica , Enfermedades Mitocondriales , Cuidadores , Prioridades en Salud , Humanos , Enfermedades Mitocondriales/diagnóstico , Enfermedades Mitocondriales/genética , Enfermedades Mitocondriales/terapia , Encuestas y Cuestionarios
3.
Brain ; 143(11): 3242-3261, 2020 12 05.
Artículo en Inglés | MEDLINE | ID: mdl-33150406

RESUMEN

Heterozygous mutations in KMT2B are associated with an early-onset, progressive and often complex dystonia (DYT28). Key characteristics of typical disease include focal motor features at disease presentation, evolving through a caudocranial pattern into generalized dystonia, with prominent oromandibular, laryngeal and cervical involvement. Although KMT2B-related disease is emerging as one of the most common causes of early-onset genetic dystonia, much remains to be understood about the full spectrum of the disease. We describe a cohort of 53 patients with KMT2B mutations, with detailed delineation of their clinical phenotype and molecular genetic features. We report new disease presentations, including atypical patterns of dystonia evolution and a subgroup of patients with a non-dystonic neurodevelopmental phenotype. In addition to the previously reported systemic features, our study has identified co-morbidities, including the risk of status dystonicus, intrauterine growth retardation, and endocrinopathies. Analysis of this study cohort (n = 53) in tandem with published cases (n = 80) revealed that patients with chromosomal deletions and protein truncating variants had a significantly higher burden of systemic disease (with earlier onset of dystonia) than those with missense variants. Eighteen individuals had detailed longitudinal data available after insertion of deep brain stimulation for medically refractory dystonia. Median age at deep brain stimulation was 11.5 years (range: 4.5-37.0 years). Follow-up after deep brain stimulation ranged from 0.25 to 22 years. Significant improvement of motor function and disability (as assessed by the Burke Fahn Marsden's Dystonia Rating Scales, BFMDRS-M and BFMDRS-D) was evident at 6 months, 1 year and last follow-up (motor, P = 0.001, P = 0.004, and P = 0.012; disability, P = 0.009, P = 0.002 and P = 0.012). At 1 year post-deep brain stimulation, >50% of subjects showed BFMDRS-M and BFMDRS-D improvements of >30%. In the long-term deep brain stimulation cohort (deep brain stimulation inserted for >5 years, n = 8), improvement of >30% was maintained in 5/8 and 3/8 subjects for the BFMDRS-M and BFMDRS-D, respectively. The greatest BFMDRS-M improvements were observed for trunk (53.2%) and cervical (50.5%) dystonia, with less clinical impact on laryngeal dystonia. Improvements in gait dystonia decreased from 20.9% at 1 year to 16.2% at last assessment; no patient maintained a fully independent gait. Reduction of BFMDRS-D was maintained for swallowing (52.9%). Five patients developed mild parkinsonism following deep brain stimulation. KMT2B-related disease comprises an expanding continuum from infancy to adulthood, with early evidence of genotype-phenotype correlations. Except for laryngeal dysphonia, deep brain stimulation provides a significant improvement in quality of life and function with sustained clinical benefit depending on symptoms distribution.


Asunto(s)
Trastornos Distónicos/genética , N-Metiltransferasa de Histona-Lisina/genética , Adolescente , Adulto , Niño , Preescolar , Deleción Cromosómica , Estudios de Cohortes , Simulación por Computador , Estimulación Encefálica Profunda , Progresión de la Enfermedad , Trastornos Distónicos/terapia , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/genética , Femenino , Retardo del Crecimiento Fetal/genética , Trastornos Neurológicos de la Marcha/etiología , Trastornos Neurológicos de la Marcha/terapia , Humanos , Enfermedades de la Laringe/etiología , Enfermedades de la Laringe/terapia , Masculino , Mutación , Mutación Missense , Fenotipo , Calidad de Vida , Resultado del Tratamiento , Adulto Joven
5.
Neurogenetics ; 18(1): 49-55, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-28063088

RESUMEN

Charcot-Marie-Tooth disease (CMT) refers to a genetically heterogeneous group of disorders which cause a peripheral motor and sensory neuropathy. The overall prevalence is 1 in 2500 individuals. Mutations in the MFN2 gene are the commonest cause for the axonal (CMT2) type. We describe a Caucasian 5-year old girl affected by CMT2A since the age of 2 years. She presented with unsteady gait, in-turning of the feet and progressive foot deformities. Nerve conduction studies suggested an axonal neuropathy and molecular testing identified a previously reported pathogenic variant c.1090C > T, p.(Arg364Trp) in the MFN2 gene. This variant was also detected in a mosaic state in blood and saliva by Sanger sequencing in her subjectively healthy father. Next generation sequencing showed that the level of mosaicism was 21% in blood and 24% in saliva. A high recurrence risk was given because the father had proven somatic mosaicism and an affected child implying gonadal mosaicism. The parents were referred for pre-implantation genetic diagnosis. To the best of our knowledge, this is the first reported case of somatic mosaicism for MFN2. This study has important implications for genetic counselling in families with CMT2A.


Asunto(s)
Enfermedad de Charcot-Marie-Tooth/genética , Enfermedad de Charcot-Marie-Tooth/patología , GTP Fosfohidrolasas/genética , Proteínas Mitocondriales/genética , Mosaicismo , Mutación Missense , Adulto , Preescolar , Relaciones Padre-Hijo , Femenino , Humanos , Masculino , Núcleo Familiar , Padres , Linaje , Fenotipo , Índice de Severidad de la Enfermedad
6.
Brain ; 137(Pt 4): 1009-18, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24578548

RESUMEN

Episodic ataxia type 1 is considered a rare neuronal ion channel disorder characterized by brief attacks of unsteadiness and dizziness with persistent myokymia. To characterize the natural history, develop outcome measures for future clinical trials, and correlate genotype with phenotype, we undertook an international, prospective, cross-sectional study. Thirty-nine individuals (51% male) were enrolled: median age 37 years (range 15-65 years). We identified 10 different pathogenic point mutations in KCNA1 that accounted for the genetic basis of 85% of the cohort. Participants with KCNA1 mutations were more likely to have a positive family history. Analysis of the total cohort showed that the first episode of ataxia occurred before age 20 in all but one patient, with an average age of onset of 7.9 years. Physical exertion, emotional stress and environmental temperature were the most common triggers for attacks. Attack frequency ranged from daily to monthly, even with the same KCNA1 genotype. Average attack duration was in the order of minutes. Ten participants (26%) developed permanent cerebellar signs, which were related to disease duration. The average Scale for the Assessment and Rating of Ataxia score (SARA, a standardized measure of cerebellar dysfunction on clinical examination, scores range from 0-40) was an average of 3.15 for all participants (range 0-14), but was only 2 in those with isolated episodic ataxia compared with 7.7 in those with progressive cerebellar ataxia in addition to episodic ataxia. Thirty-seven participants completed the SF-36, a quality of life survey; all eight domain norm-based average scores (mean=50) were below normal with mental health being the lowest (41.3) in those with mutation positive episodic ataxia type 1. Scores on SF-36 correlated negatively with attack frequency. Of the 39 participants in the study, 33 harboured mutations in KCNA1 whereas the remaining six had no mutation identified. Episodic ataxia type 1 phenocopies have not been described previously and we report their clinical features, which appear to be different to those with a KCNA1 mutation. This large prospective study of both genetically confirmed episodic ataxia type 1 and episodic ataxia type 1 phenocopies provides detailed baseline characteristics of these disorders and their impact on participants. We found that attacks had a significant effect on quality of life. Unlike previous studies, we found that a significant number of individuals with genetically confirmed episodic ataxia type 1 (21%) had accumulated persistent cerebellar symptoms and signs. These data will enable the development of outcome measures for clinical trials of treatment.


Asunto(s)
Ataxia/genética , Ataxia/psicología , Estudios de Asociación Genética , Miocimia/genética , Miocimia/psicología , Calidad de Vida , Adolescente , Adulto , Edad de Inicio , Anciano , Ataxia/complicaciones , Estudios Transversales , Femenino , Humanos , Canal de Potasio Kv.1.1/genética , Masculino , Persona de Mediana Edad , Miocimia/complicaciones , Mutación Puntual , Adulto Joven
7.
Handb Clin Neurol ; 203: 123-133, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39174244

RESUMEN

The primary episodic ataxias (EAs) are a group of autosomal-dominant disorders characterized by transient recurrent incoordination and truncal instability, often triggered by physical exertion or emotional stress and variably associated with progressive baseline ataxia. There are now nine designated subtypes EA1-9 (OMIM) and late onset cerebellar ataxia with episodic features as newly designated SCA27B, based largely on genetic loci. Mutations have been identified in multiple individuals and families in 4 of the 9 EA subtypes, mostly with the onset before adulthood. This chapter focuses on the clinical assessment and management of EA, genetic diagnosis, and neurophysiologic consequences of the causative mutations in the best characterized EA syndromes: EA1 caused by mutations in KCNA1 encoding a neuronal voltage-gated potassium channel, EA2 caused by mutations in CACNA1A encoding a neuronal voltage-gated calcium channel, EA6 caused by mutations in SLC1A3 encoding a glutamate transporter that is also an anion channel, and SCA27B with late onset episodic ataxia caused by an intronic trinucleotide repeat in FGF14 encoding fibroblast growth factor 14 important in regulating the distribution of voltage-gated sodium channels in the cerebellar Purkinje and granule cells. The study of EA has illuminated previously unrecognized but important roles of ion channels and transporters in brain function with shared mechanisms underlying cerebellar ataxia, migraine, and epilepsy.


Asunto(s)
Ataxia , Mutación , Humanos , Ataxia/genética , Ataxia/diagnóstico , Mutación/genética , Factores de Crecimiento de Fibroblastos/genética , Canal de Potasio Kv.1.1/genética , Canales de Calcio/genética , Transportador 1 de Aminoácidos Excitadores
8.
J Physiol ; 588(Pt 11): 1905-13, 2010 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-20156848

RESUMEN

Mutations in CACNA1A, which encodes the principal subunit of the P/Q calcium channel, underlie episodic ataxia type 2 (EA2). In addition, some patients with episodic ataxia complicated by epilepsy have been shown to harbour CACNA1A mutations, raising the possibility that P/Q channel dysfunction may be linked to human epilepsy. We undertook a review of all published CACNA1A EA2 cases and this showed that 7% have epilepsy--representing a sevenfold increased epilepsy risk compared to the background population risk (P<0.001). We also studied a series of 17 individuals with episodic ataxia accompanied by epilepsy and/or clearly epileptiform electroencephalograms (EEGs). We screened the entire coding region of CACNA1A for point mutations and rearrangements to determine if genetic variation in the gene is associated with the epilepsy phenotype, and measured the functional impact of all missense variations on heterologously expressed P/Q channels. We identified two large scale deletions and two new missense mutations in CACNA1A. When expressed, L621R had little detectable effect on P/Q channel function, while the other missense change, G540R, caused an approximately 30% reduction in current density. In nine patients we also identified the previously reported non-synonymous coding variants (E921D and E993V) which also resulted in impairment of P/Q channel function. Taken together, 12 of the 17 patients have genetic changes which decrease P/Q channel function. We conclude that variants in the coding region of CACNA1A that confer a loss of P/Q-type channel function are associated with episodic ataxia and epilepsy. Our data suggest that functional stratification of all variants, including common polymorphisms, rare variants and novel mutations, may provide new insights into the mechanisms of channelopathies.


Asunto(s)
Ataxia/genética , Ataxia/fisiopatología , Canales de Calcio/genética , Epilepsia/genética , Epilepsia/fisiopatología , Adolescente , Adulto , Ataxia/complicaciones , Canales de Calcio/fisiología , Línea Celular , Niño , Preescolar , ADN/genética , Electroencefalografía , Electrofisiología , Epilepsia/complicaciones , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Mutación/genética , Mutación Missense/genética , Técnicas de Placa-Clamp , Mutación Puntual/genética , Mutación Puntual/fisiología , Polimorfismo de Nucleótido Simple , Adulto Joven
9.
Neurobiol Dis ; 32(1): 10-5, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18606230

RESUMEN

Premature stop codons in CACNA1A, which encodes the alpha(1A) subunit of neuronal P/Q-type (Ca(V)2.1) Ca(2+) channels, cause episodic ataxia type 2 (EA2). CACNA1A undergoes extensive alternative splicing, which contributes to the pharmacological and kinetic heterogeneity of Ca(V)2.1-mediated Ca(2+) currents. We identified three novel heterozygous stop codon mutations associated with EA2 in an alternately spliced exon (37A), which encodes part of an EF-hand motif required for Ca(2+)-dependent facilitation. One family had a C to G transversion (Y1854X). A dinucleotide deletion results in the same premature stop codon in a second family, and a further single nucleotide change leads to a different truncation (R1858X) in a de novo case of EA2. Expression studies of the Y1854X mutation revealed loss of Ca(V)2.1-mediated current. Because these mutations do not affect the alternate exon 37B, these findings reveal unexpected dependence of cerebellar function on intact exon 37A-containing Ca(V)2.1 channels.


Asunto(s)
Empalme Alternativo/genética , Canales de Calcio Tipo N/genética , Codón sin Sentido/genética , Motivos EF Hand/genética , Mutación del Sistema de Lectura/genética , Isoformas de Proteínas/genética , Ataxias Espinocerebelosas/genética , Adulto , Animales , Cerebelo/química , Cerebelo/fisiopatología , Codón sin Sentido/química , Exones/genética , Femenino , Variación Genética/genética , Humanos , Masculino , Linaje , Isoformas de Proteínas/química , Ataxias Espinocerebelosas/diagnóstico , Ataxias Espinocerebelosas/fisiopatología , Xenopus laevis
10.
Lancet Neurol ; 6(11): 970-80, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17913586

RESUMEN

BACKGROUND: The Epilepsy Genetics (EPIGEN) Consortium was established to undertake genetic mapping analyses with augmented statistical power to detect variants that influence the development and treatment of common forms of epilepsy. METHODS: We examined common variations across 279 prime candidate genes in 2717 case and 1118 control samples collected at four independent research centres (in the UK, Ireland, Finland, and Australia). Single nucleotide polymorphism (SNP) and combined set-association analyses were used to examine the contribution of genetic variation in the candidate genes to various forms of epilepsy. FINDINGS: We did not identify clear, indisputable common genetic risk factors that contribute to selected epilepsy subphenotypes across multiple populations. Nor did we identify risk factors for the general all-epilepsy phenotype. However, set-association analysis on the most significant p values, assessed under permutation, suggested the contribution of numerous SNPs to disease predisposition in an apparent population-specific manner. Variations in the genes KCNAB1, GABRR2, KCNMB4, SYN2, and ALDH5A1 were most notable. INTERPRETATION: The underlying genetic component to sporadic epilepsy is clearly complex. Results suggest that many SNPs contribute to disease predisposition in an apparently population-specific manner. However, subtle differences in phenotyping across cohorts, combined with a poor understanding of how the underlying genetic component to epilepsy aligns with current phenotypic classifications, might also account for apparent population-specific genetic risk factors. Variations across five genes warrant further study in independent cohorts to clarify the tentative association.


Asunto(s)
Mapeo Cromosómico , Epilepsia/genética , Convulsiones/genética , Adulto , Estudios de Casos y Controles , Estudios de Cohortes , Predisposición Genética a la Enfermedad , Variación Genética , Genotipo , Humanos , Canal de Potasio Kv1.3/genética , Subunidades beta de los Canales de Potasio de Gran Conductancia Activados por el Calcio/genética , Proteínas del Tejido Nervioso/genética , Fenotipo , Polimorfismo de Nucleótido Simple , Receptores de GABA-A , Receptores de GABA-B/genética , Succionato-Semialdehído Deshidrogenasa/genética , Sinapsinas/genética , Síndrome
11.
Ann Thorac Surg ; 74(1): 261-3, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12118781

RESUMEN

We discuss the case of a young man with mediastinal tuberculosis who presented with pericarditis, thymic involvement, and respiratory failure because of upper airway obstruction. Although mediastinal tuberculosis is not uncommon, the simultaneous occurrence of these complications is exceedingly rare and in this patient resulted in an acute life-threatening illness. The diagnosis and treatment of this condition can be complex, and these aspects of the patient's care are discussed.


Asunto(s)
Obstrucción de las Vías Aéreas/etiología , Derrame Pericárdico/etiología , Insuficiencia Respiratoria/etiología , Timo , Tuberculosis Ganglionar/complicaciones , Adulto , Obstrucción de las Vías Aéreas/terapia , Humanos , Masculino , Respiración Artificial , Insuficiencia Respiratoria/terapia , Tuberculosis Ganglionar/diagnóstico
14.
Arch Neurol ; 68(5): 653-5, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21555642

RESUMEN

OBJECTIVES: To highlight an unexpected clinical presentation and to review the associated polyneuropathy phenotypes of SCA3. DESIGN: Clinical follow-up. SETTING: Neurological referral center. PATIENT: Middle-aged man with no family history for SCA3. RESULTS: Presentation with an isolated axonal, distal, symmetric, sensorimotor polyneuropathy for 6 years before developing a cerebellar syndrome prompting genetic testing for SCA3. CONCLUSION: SCA3 can present with an isolated axonal, distal, symmetric, sensorimotor polyneuropathy.


Asunto(s)
Axones , Neuropatía Hereditaria Motora y Sensorial/genética , Enfermedad de Machado-Joseph/diagnóstico , Enfermedad de Machado-Joseph/genética , Proteínas del Tejido Nervioso/genética , Proteínas Nucleares/genética , Proteínas Represoras/genética , Ataxina-3 , Axones/metabolismo , Diagnóstico Diferencial , Humanos , Enfermedad de Machado-Joseph/metabolismo , Masculino , Persona de Mediana Edad , Polineuropatías/genética , Expansión de Repetición de Trinucleótido
16.
J Neurol Sci ; 285(1-2): 238-40, 2009 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-19560788

RESUMEN

Metronidazole-induced central nervous system (CNS) toxicity causes a spectrum of neurological symptoms including ataxia, encephalopathy and peripheral neuropathy. It is associated with characteristic MRI changes of high signal intensity in the dentate nuclei. Given the increasing use of metronidazole, it is import to recognise this drug as a cause of ataxia, as it is entirely reversible on drug withdrawal.


Asunto(s)
Antiinfecciosos/efectos adversos , Ataxia/inducido químicamente , Metronidazol/efectos adversos , Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Ataxia/patología , Encéfalo/efectos de los fármacos , Encéfalo/patología , Estudios de Seguimiento , Humanos , Trasplante de Riñón , Imagen por Resonancia Magnética , Masculino , Metronidazol/farmacología , Metronidazol/uso terapéutico , Persona de Mediana Edad , Trasplante de Páncreas
18.
Neurology ; 65(2): 308-10, 2005 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-16043807

RESUMEN

Episodic ataxia type 2 (EA2) is an autosomal dominant channelopathy characterized by paroxysmal cerebellar ataxia. Previous studies suggest that most EA2 cases are associated with mutations in the alpha1A subunit of the P/Q-type voltage-gated calcium channel gene CACNA1A. In a UK national study, the authors analyzed 15 index cases with typical EA2 and identified two unreported intronic mutations that predict aberrant splicing.


Asunto(s)
Empalme Alternativo/genética , Canales de Calcio/genética , Ataxia Cerebelosa/genética , Mutación/genética , ARN/genética , Adolescente , Adulto , Ataxia Cerebelosa/metabolismo , Ataxia Cerebelosa/fisiopatología , Niño , Preescolar , Mapeo Cromosómico , Cromosomas Humanos Par 19/genética , Análisis Mutacional de ADN , Femenino , Genes Dominantes , Marcadores Genéticos/genética , Predisposición Genética a la Enfermedad/genética , Pruebas Genéticas , Humanos , Lactante , Intrones/genética , Masculino , Linaje , Polimorfismo Genético/genética , Subunidades de Proteína/genética , Sitios de Empalme de ARN/genética , Reino Unido
19.
Epilepsy Curr ; 8(2): 37-8, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18330464
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA